KG 4/2015: A randomized, controlled, multicenter, open-label phase III clinical trial of GV1001 with gemcitabine/capecitabine in previous untreated, eotaxin-high patients with advanced pancreatic ductal adenocarcinoma.

Jung Hyun Jo,Yong Tae Kim,Ho-Soon Choi,Ho Gak Kim,Hong Sik Lee,Young Woo Choi,Dong Uk Kim,Kwang Hyuck Lee,Eui Joo Kim,Jeong Ho Han,Seung-Ok Lee,Chang Hwan Park,Eun Kwang Choi,Kyong Joo Lee,Jae Yong Cho,Woojin Lee,Si Young Song

KG 4/2015: A randomized, controlled, multicenter, open-label phase III clinical trial of GV1001 with gemcitabine/capecitabine in previous untreated, eotaxin-high patients with advanced pancreatic ductal adenocarcinoma.

2021

Jung Hyun Jo
Yong Tae Kim
Ho-Soon Choi
Ho Gak Kim
Hong Sik Lee
Young Woo Choi
Dong Uk Kim
Kwang Hyuck Lee
Eui Joo Kim
Jeong Ho Han
Seung-Ok Lee
Chang Hwan Park
Eun Kwang Choi
Kyong Joo Lee
Jae Yong Cho
Woojin Lee
Si Young Song

4020Background: In the TeloVac study, GV1001 with Gemcitabine/capecitabine (G/C) did not show increased overall survival (OS) than G/C in patients (pts) with advanced pancreatic ductal adenocarcino...

Keywords:

Medicine
Internal medicine
Gemcitabine
overall survival
Eotaxin
Gastroenterology
Clinical trial
Capecitabine
open label
pancreatic ductal adenocarcinoma
pancreatic carcinoma

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations